Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feng Bi

Showing results (21-30 of 350) with videos related to

Pageof 35
Sort By:
Molecular Cancer|November 7, 2021
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancerGongmin Zhu, Lijiao Pei, Hongwei Xia, et al.
International Journal of Oncology|October 5, 2022
[Corrigendum] miR‑200b/c targets the expression of RhoE and inhibits the proliferation and invasion of non‑small cell lung cancer cellsQiulin Tang, Mingxing Li, Liang Chen, et al.
Frontiers in Oncology|September 12, 2022
Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapyYuheng Zou, Hongying Zhang, Feng Bi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 24, 2021
PKM2 compensates for proteasome dysfunction by mediating the formation of the CHIP-HSP70-BAG3 complex and the aggregation of ubiquitinated proteinsChenliang Zhang, Qiulin Tang, Hongwei Xia, et al.
Cancer Biology & Medicine|January 17, 2023
Major roles of the circadian clock in cancerChen Huang, Chenliang Zhang, Yubin Cao, et al.
Molecular Medicine Reports|October 24, 2014
MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cellsXiaojun Ge, Limei Zheng, Min Huang, et al.
Medical Oncology (Northwood, London, England)|April 1, 2014
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese populationYe Chen, Dan Cao, Feng Bi, et al.
Frontiers in Oncology|March 31, 2023
A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancerPeng Chen, Feng Bi, Weili Tan, et al.
Molecular Cancer Therapeutics|September 27, 2019
Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK PathwaySheng Zhou, Huanji Xu, Qiulin Tang, et al.
Cancer Letters|November 16, 2018
Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancersXinyu Dai, Hongwei Xia, Sheng Zhou, et al.
Pageof 35

Showing results (21-30 of 350) with videos related to

Sort By:
Pageof 35
Molecular Cancer|November 7, 2021
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancerGongmin Zhu, Lijiao Pei, Hongwei Xia, et al.
International Journal of Oncology|October 5, 2022
[Corrigendum] miR‑200b/c targets the expression of RhoE and inhibits the proliferation and invasion of non‑small cell lung cancer cellsQiulin Tang, Mingxing Li, Liang Chen, et al.
Frontiers in Oncology|September 12, 2022
Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapyYuheng Zou, Hongying Zhang, Feng Bi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 24, 2021
PKM2 compensates for proteasome dysfunction by mediating the formation of the CHIP-HSP70-BAG3 complex and the aggregation of ubiquitinated proteinsChenliang Zhang, Qiulin Tang, Hongwei Xia, et al.
Cancer Biology & Medicine|January 17, 2023
Major roles of the circadian clock in cancerChen Huang, Chenliang Zhang, Yubin Cao, et al.
Molecular Medicine Reports|October 24, 2014
MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cellsXiaojun Ge, Limei Zheng, Min Huang, et al.
Medical Oncology (Northwood, London, England)|April 1, 2014
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese populationYe Chen, Dan Cao, Feng Bi, et al.
Frontiers in Oncology|March 31, 2023
A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancerPeng Chen, Feng Bi, Weili Tan, et al.
Molecular Cancer Therapeutics|September 27, 2019
Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK PathwaySheng Zhou, Huanji Xu, Qiulin Tang, et al.
Cancer Letters|November 16, 2018
Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancersXinyu Dai, Hongwei Xia, Sheng Zhou, et al.
Pageof 35